CTOR

Citius Oncology, Inc.

Insider Trades

ActorHolding ValueLast TransactionAmountTransaction PriceCurrent Price
Bartushak JaimeChief Financial Officer
--825k shares
Grant / ExerciseSep 19, 2025
Disclosure amount unavailable825k shares
--
--
Czuczman MyronChief Medical Officer
--825k shares
Grant / ExerciseSep 19, 2025
Disclosure amount unavailable825k shares
--
--
Dutia Suren GDirector
--300k shares
Grant / ExerciseSep 19, 2025
Disclosure amount unavailable300k shares
--
--
Holubiak Myron ZDirector, Officer: Secretary
--100k shares
Grant / ExerciseSep 19, 2025
Disclosure amount unavailable100k shares
--
--
Holubiak Myron ZDirector, Officer: Secretary
--850k shares
Grant / ExerciseSep 19, 2025
Disclosure amount unavailable850k shares
--
--
Holuka Eugene MyronDirector
--300k shares
Grant / ExerciseSep 19, 2025
Disclosure amount unavailable300k shares
--
--

News

prnewswire.comCitius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignanciesprnewswire.comJun 1prnewswire.comCitius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meetingprnewswire.comMay 26prnewswire.comCitius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Updateprnewswire.comMay 15prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Updateprnewswire.comMay 15prnewswire.comCitius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercializationprnewswire.comMay 5